Shattuck Labs, Inc.
NASDAQ:STTK
1.34 (USD) • At close October 29, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Shattuck Labs, Inc. |
Symbool | STTK |
Munteenheid | USD |
Prijs | 1.34 |
Beurswaarde | 63,954,582 |
Dividendpercentage | 0% |
52-weken bereik | 1.07 - 11.76 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Taylor H. Schreiber M.D., Ph.D. |
Website | https://www.shattucklabs.com |
An error occurred while fetching data.
Over Shattuck Labs, Inc.
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)